Ending the tuberculosis syndemic: is COVID-19 the (in)convenient scapegoat for poor progress?
- PMID: 35338839
- PMCID: PMC8942476
- DOI: 10.1016/S2213-2600(22)00123-0
Ending the tuberculosis syndemic: is COVID-19 the (in)convenient scapegoat for poor progress?
Conflict of interest statement
MXR is the recipient of a Wellcome Trust Investigator Award on tuberculosis and diabetes. IA is the recipient of an EU funded award to End-VOC (End SARS-CoV-2 variants of concern). The authors declare no other competing interests.
Comment on
-
The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions.Lancet Respir Med. 2022 Jun;10(6):603-622. doi: 10.1016/S2213-2600(22)00092-3. Epub 2022 Mar 23. Lancet Respir Med. 2022. PMID: 35338841 Free PMC article. Review.
References
-
- Singer M. Syndemics and the biosocial conception of health. Lancet. 2017;389:941–950. - PubMed
-
- WHO . World Health Organization; Geneva: 2021. Global tuberculosis report 2021.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical